Poniard Pharmaceuticals, Inc. PFD CV$2.4375
PARDP
Other OTC0.00
USD
- -
- -
Poniard Pharmaceuticals, Inc. PFD CV$2.4375
PARDP
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Poniard Pharmaceuticals, Inc. develops and commercializes cancer therapeutics as a biopharmaceutical company focused on oncology treatments. The company advances picoplatin, a platinum-based chemotherapy agent designed to overcome platinum resistance in solid tumors, for multiple indications including small cell lung cancer, colorectal cancer, prostate cancer, and ovarian cancer; it has completed a Phase III SPEAR trial of intravenous picoplatin as second-line therapy for small cell lung cancer, Phase II trials in first-line metastatic colorectal cancer and castration-resistant prostate cancer, and a Phase I trial of an oral picoplatin formulation in solid tumors. Founded in 1984 as NeoRx Corporation and renamed Poniard Pharmaceuticals in 2006, the company is headquartered in Seattle, Washington, with operations primarily in the United States; it employs approximately eight people and trades on OTC Markets under tickers PARD and preferred shares PARDP. In recent years, the company has reported no sales or net income, reflecting a dormant operational status with stock prices near zero; its last major activities included a 2011 merger agreement with Allozyne, Inc., which combined oncology assets with autoimmune therapies but ultimately fell through, alongside earlier strategic shifts such as suspending small cell lung cancer regulatory efforts in 2010 to pursue other indications and workforce reductions.